Search company, investor...

Morria Biopharmaceuticals


Other Investors | Alive

About Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

Headquarters Location

53 Davies street Mayfair


United Kingdom

Missing: Morria Biopharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Morria Biopharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Morria Biopharmaceuticals News

Morria Biopharmaceuticals Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer

Jan 23, 2013

NEW YORK, NY--(Marketwire - Jan 23, 2013) - Morria Biopharmaceuticals Plc (the "Company"), an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that Dr. Alan Harris has joined the Company full time as Chief Medical Officer. Dr. Harris was initially recruited to Morria in July 2012 in a part time capacity. He will develop and lead the clinical development programs for Morria's Multi-Functional Anti-Inflammatory Drug candidates including MRX-4 in allergic rhinitis, and MRX-6 in dermatitis. Dr. David Sidransky, director of Morria and former Vice Chairman of ImClone Systems, now a wholly-owned subsidiary of Eli Lilly and Company, commented, "We are delighted to have Alan come on board as full time Chief Medical Officer. He has an excellent track record in the pharmaceutical industry, in particular in the development of blockbuster anti-inflammatory medications such as Claritin® and Nasonex®. His transition to a permanent role comes at an important time for Morria, as we prepare to move forward with additional clinical studies for our lead product candidates in allergic rhinitis and dermatology. " "There is a great opportunity to develop a completely new class of anti-inflammatory therapeutics at Morria," said Dr. Harris. "From my experience in this area, I see the drug platform of Morria as having the potential to be truly transformative in the development of safer treatment options for patients. I look forward to assuming a larger role at Morria in 2013. "  Dr. Harris started his career in the pharmaceutical industry in 1984 when he joined Sandoz (Novartis) in Switzerland as international clinical project leader and headed the clinical development of a major therapeutic peptide breakthrough therapy, octreotide (Sandostatin®), the first long-acting somatostatin analog approved worldwide for the treatment of malignant hormone producing gastrointestinal and pancreatic endocrine tumors and growth hormone-producing pituitary tumors. Between 1995 and 2003, Dr. Harris worked at Schering-Plough and became a VP of Global Healthcare Research. As one of his key responsibilities, Dr. Harris led the Medical Affairs clinical development program of the anti-allergy medicine Claritin®, which became the leading non-sedating antihistamine worldwide. Claritin® sales grew from $400 million in 1995 to $3.2 billion in 2001. Dr. Harris also led the Medical Affairs clinical development program of other allergy franchise products including Nasonex®, Elocon, and Asmanex (which all contain mometasone furoate -- a synthetic corticosteroid with anti-inflammatory activity). Nasonex sales rose to $1.2 B in 2011. His research on the effect of antihistamines on allergic inflammation and congestion associated with rhinitis and asthma has influenced the redefinition of these associated conditions and their treatment. From 2004 to 2006, Dr. Harris worked at Pfizer as Therapeutic Head of Endocrine Care in the Worldwide Medical Department. While at Pfizer, he oversaw the Medical Affairs clinical development program of the human recombinant growth hormone (GH) Genotropin for the treatment of pediatric short stature conditions and adult GH deficiency and of the GH antagonist Pegvisomant for the treatment of GH-producing pituitary tumors. Since 2006, Dr. Harris has served as Chief Medical Officer and VP of Drug Development at a number of companies. Dr. Harris is currently an Adjunct Professor of Medicine at NYU Langone Medical School. He was previously an Associate Professor of Medicine at Cedars Sinai Medical Center, UCLA School of Medicine. Dr. Harris is a fellow of the American College of Physicians, the Royal College of Physicians (U.K.) and the Royal Society of Medicine. He has served on the editorial boards of several international peer reviewed medical journals and has authored more than 120 peer reviewed scientific papers. Dr. Harris received his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in Endocrinology from Erasmus University, Rotterdam, The Netherlands. About Morria Biopharmaceuticals Morria Biopharmaceuticals is an emerging growth biopharmaceutical company focused on the development of first-in-class, non-steroidal, synthetic anti-inflammatory drugs. Morria has developed a class of synthetic drugs termed MFAIDs (Multi-Functional Anti-Inflammatory Drugs) representing a new class and therapeutic platform for the treatment of a wide range of inflammatory diseases such as allergies and autoimmune diseases. Morria currently has two lead product candidates in its clinical pipeline, both of which have completed first-in-patient clinical studies: MRX-4, a nasal spray for treating allergic rhinitis (hay fever), and MRX-6, a topical cream for treating contact dermatitis (a common type of eczema); and pre-clinical programs in ophthalmology and inflammatory bowel disease. Morria's business strategy is to expand and build a biopharmaceutical business to focus on a spectrum of inflammatory diseases based on its current and upcoming first-in-class product candidates that will address the current unmet need for safe and potent alternatives to steroids. . Forward Looking Statement Safe Harbor This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements. Contact Information

Morria Biopharmaceuticals Frequently Asked Questions (FAQ)

  • What is Morria Biopharmaceuticals's latest funding round?

    Morria Biopharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Morria Biopharmaceuticals?

    Investors of Morria Biopharmaceuticals include Charles Street Securities.

  • Who are Morria Biopharmaceuticals's competitors?

    Competitors of Morria Biopharmaceuticals include Humanetics, Charleston Laboratories, Deciphera Pharmaceuticals, GC-Rise Pharmaceutical, Akebia Therapeutics, Xigen, VIA Pharmaceuticals, Targanta Therapeutics, Inflabloc Pharmaceuticals, ARYX Therapeutics and 15 more.

Compare Morria Biopharmaceuticals to Competitors

Inflabloc Pharmaceuticals

Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.


Nutrinia is a neonatology company focused on developing a proprietary oral formulation of insulin for gastrointestinal indications in infants.

Choice Research of Birmingham

Choice Research of Birmingham is a company that manages clinical development trials.

InClinica Logo

InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.